VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | The need for disease-modifying drugs in myelofibrosis

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, describes current challenges in myelofibrosis management. The approval of various JAK inhibitors have improved outcomes in patients and research into BET inhibitors will add to the current armamentarium. However, there is a demand for disease-modifying compounds that can improve overall survival (OS). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter